Report of Foreign Issuer (6-k)
August 17 2016 - 9:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of August 2016
Commission
File Number: 001-37643
KITOV
PHARMACEUTICALS HOLDINGS
LTD.
(Translation
of registrant's name into English)
One
Azrieli Center, Round Tower, 23
rd
Floor,
Tel
Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
August 17, 2016, Kitov Pharmaceuticals Holdings
Ltd. (the “Company” or the “Registrant”) issued
a Press Release: “
Kitov Pharmaceuticals Issues First Half 2016 Financial Reports.
” A copy of this press release,
together with the Company’s unaudited condensed consolidated interim financial statements as of June 30, 2016, and for the
six months then ended, are furnished herewith as Exhibits 99.1 and 99.2, respectively.
This
report on Form 6-K of the Registrant consists of the following documents, which are attached hereto:
Exhibits
99.1
|
Press
Release
|
99.2
|
The
Registrant’s unaudited condensed consolidated interim financial statements as of June 30, 2016, and for the six months
then ended.
|
The information contained within this report on Form
6-K and all Exhibits attached hereto should be read in conjunction with (1) our Unaudited Condensed Consolidated Interim Financial
Statements as of June 30, 2016, and for the six months then ended; and, (2) our audited consolidated financial statements for the
year ended December 31, 2015, which appears in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange
Commission on March 18, 2016, as well as the other information contained in such Annual Report on Form 20-F and in our Registration
Statement on Form F-1 filed with the SEC (file number 333-211477).
The text which is found under the headings entitled
“Financial Results for Six Months Ended June 30, 2016” and “Balance Sheet Highlights”, respectively, in
Exhibit 99.1 attached hereto; and, the entire Exhibit 99.2 attached hereto, are all hereby incorporated by reference into the
Registration Statement on Form S-8 filed by the registrant under the Securities Act of 1933 on May 20, 2016.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV
PHARMACEUTICALS HOLDINGS LTD.
|
|
|
|
August
17, 2016
|
By:
|
/s/
Avraham Ben-Tzvi
|
|
|
Avraham
Ben-Tzvi
|
|
|
General
Counsel & Company Secretary
|
3
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024